Interleukins and Haematopoietic Growth Factors

  • F. M. Rosenthal
  • A. Lindemann
  • F. Herrmann
  • R. Mertelsmann
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


One of the most challenging areas of contemporary oncological and immunological research is represented by investigation of the potential clinical use of human cytokines.


Renal Cell Carcinoma Hairy Cell Leukemia Recombinant Human Erythropoietin Haematopoietic Growth Factor Recombinant Leukocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nicola NA: Why do hematopoietic growth factor receptors interact with each other? Immunol Today 1987 (8):134–139.CrossRefGoogle Scholar
  2. 2.
    Hueber K, Isobe M, Croce CM, Golde DM, Kaufman SE, Gasson JC: The human gene encoding GM-CSF is a 5q29-q32, the chromosome region deleted in the 5q-anomaly. Science 1985 (230):1282–1285.CrossRefGoogle Scholar
  3. 3.
    Donahue RE, Wang EA, Foutch L, Leary AC, Witek-Giametti JS, Metzger M, Hewick RM, Steinbrink DR, Shaw G: Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF. Cold Spring Harbour Symp Quant Biol 1986 (51):685–692.Google Scholar
  4. 4.
    Herrmann F, Oster W, Meuer SC, Klein K, Lindemannn A, Mertelsmann R: Interleukin-1 stimulates T lymphocytes to produce GM-CSF. J Clin Invest 1988 (81):1415–1418.PubMedCrossRefGoogle Scholar
  5. 5.
    Donahue RE, Emerson SG, Wang EA, Wong GG, Clark SC, Nathan DG: Demonstration of burst-promoting activity of recombinant human GM-CSF on circulating erythroid progenitors using an assay involving the delayed addition of erythropoietin. Blood 1985 (66):1479–1481.PubMedGoogle Scholar
  6. 6.
    Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, Williamson DJ, Wong GG, Clark SC, Wang EA: Biologic properties in vitro of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986 (67):37–45.PubMedGoogle Scholar
  7. 7.
    Lindemann A, Riedel D, Oster W, Meuer SC, Blohm D, Mertelsmann R, Herrmann F: GM-CSF induces secretion of interleukin-1 by polymorphonuclear neutrophils. J Immunol 1988 (140):837–839.PubMedGoogle Scholar
  8. 8.
    Herrmann F, Riedel D, Bambach T, Mertelsmann R: Recombinant granulocyte/macrophage-colony stimulating factor (RGM-CSF) inhibits growth of clonogenic cells in monoblast line U937 due to induction of tumor necrosis factor-alpha (TNF-ALPHA) and interleukin 1 (IL-1). Proc Am Soc Clin Oncol 1987 (6):A71.Google Scholar
  9. 9.
    Grabstein KH, Urdal DL, Tushinsi RJ, Mochizuki DY, Price VL, Canterell MA, Gillis S, Conlon PJ: Induction of macrophage tumoricidal activity by GM-CSF. Science 1986 (32):506–508.CrossRefGoogle Scholar
  10. 10.
    Fischer H-G, Frosch S, Reske K, Reske-Kunz AB: GM-CSF activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 1988 (141):3882–3888.PubMedGoogle Scholar
  11. 11.
    Reed SG, Nathan CF, Pihl DL, Rodricks P, Shanebeck K, Conlon PJ, Grabstein PJ: Recombinant granulocyte/macrophage colony stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide: Comparison with y-interferon. J Exp Med 1987 (166):1734–1746.PubMedCrossRefGoogle Scholar
  12. 12.
    Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R: Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: A phase Ib clinical study. Behring Inst Mitt 1988 (83):107–118.PubMedGoogle Scholar
  13. 13.
    Steis RG, Clark J, Longo DL: A phase Ib evaluation of recombinant granulocyte-macrophage colony-stimulating factor. In: Berger HG et al (eds) Cancer Therapy. Springer-Verlag, Berlin, Heidelberg 1989 pp 103–111.Google Scholar
  14. 14.
    Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R: Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989 (7):159–167.PubMedGoogle Scholar
  15. 15.
    Herrmann F, Wieser M, Schulz G, Lindemann A, Oster W, Mertelsmann R: Single daily subcutaneous administration of rhGM-CSF ameliorates hematopoietic toxicity of chemotherapy in outpatinets. Blood 1988 (72): Abstr 390.Google Scholar
  16. 16.
    Link H, Freund M, Kirchner H, Stoll M, Schmid H, Bucsky P, Seidel J, Schulz G, Schmidt RE, Riehm H, Poliwoda H, Weite K: Enhancement of autologous bone marrow transplantation with recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF). In: Berger HG et al (eds) Cancer Therapy. Springer-Verlag, Berlin, Heidelberg 1989 pp 96–102.Google Scholar
  17. 17.
    Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988 (318):869–876.PubMedCrossRefGoogle Scholar
  18. 18.
    Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988 (319):593–598.PubMedCrossRefGoogle Scholar
  19. 19.
    Ganser A, Völkers B, Greher J, Ottmann OG, Walther F, Becker R, Bergmann L, Schulz G, Hoelzer D: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes — a phase l/ll trial. Blood 1989 (73):31–37.PubMedGoogle Scholar
  20. 20.
    Ganser A, Völkers B, Greher J, Walther F, Hoelzer D: Application of granulocyte-macrophage colony-stimulating. factor in patients with malignant hematological diseases. In: Berger HG et al (eds) Cancer Therapy. Springer-Verlag, Berlin, Heidelberg 1989 pp 90–95.Google Scholar
  21. 21.
    Herrmann F, Ganser A, Lindemann A, Wieser M, Schulz G, Hoelzer D, Mertelsmann R: Stimulation of granulopoiesis in patients with malignancy by rhGM-CSF: Assessment of two routes of administration. J Biol Response Mod 1989 (in press).Google Scholar
  22. 22.
    Peters WP: The effect of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation. Sem Hematol 1989 (26):18–23.Google Scholar
  23. 23.
    Peters WP, Atwater S, Kurtzberg J: The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation. In: Gale R, Champlin R (eds) Bone Marrow Transplantation: Current Controversies. A Liss, New York 1989 pp 595–606.Google Scholar
  24. 24.
    Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD: Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1988 (1):1194–1198.PubMedCrossRefGoogle Scholar
  25. 25.
    Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. N Engl J Med 1987 (317):1545–1552.PubMedCrossRefGoogle Scholar
  26. 26.
    Herrmann F, Lindemann A, Klein H, Luebbert M, Schulz G, Mertelsmann R: Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 1989 (3):335–338.PubMedGoogle Scholar
  27. 27.
    Cannistra SA, Groshek P, Griffin JD: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine-arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989 (3):328–334.PubMedGoogle Scholar
  28. 28.
    Andreeff M, Hegewisch-Becker S, Tafuri A, Bressler J, Redner A, Haimi J, Souza L, Weite K: Recruitment of leukemic cells in vitro by colony-stimulating factors (G-CSF, GM-CSF, Interleukin-3): evidence of increased ceil kill and of differentiation by high-and low-dose cytosine arabinoside. Blut 1989 (in press).Google Scholar
  29. 29.
    Champlin RE, Nimer SD, Ireland P, Oette DH, Golde DW: Treatment of refractory aplastic anaemia with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989 (73):694–699.PubMedGoogle Scholar
  30. 30.
    Nissen C, Tichelli A, Gratwohl A, Speck B, Milne A, Gordon-Smith EC, Schaedelin J: Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anaemia patients with severe neutropenia. Blood 1988 (72):2045–2047.PubMedGoogle Scholar
  31. 31.
    Groopman J, Mitsuyasu RT, DeLero M, Oette DH, Golde DW: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immmunodeficiency syndrome. N Engl J Med 1987 (317):593–598.PubMedCrossRefGoogle Scholar
  32. 32.
    Mooney DP, Ganelli RL, O’Reeilly M, Herbert JC: Recombinant human granulocyte colony-stimulating factor and pseudomonas burn wound sepsis. Arch Surg 1988 (123):1353–1357.PubMedGoogle Scholar
  33. 33.
    Weite K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, Moore MAS: Purification and biological characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sei USA 1985 (82):1526–1530.CrossRefGoogle Scholar
  34. 34.
    Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamozo O, Hirata N, Kubota N, Oheda H, Nomura H, Ono M: Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986 (319):415–418.PubMedCrossRefGoogle Scholar
  35. 35.
    Souza LM, Boone TC, Gabrilove JL, Lai PH, Zsebok M, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Weite K: Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986 (232):61–65.PubMedCrossRefGoogle Scholar
  36. 36.
    Simmers RN, Webber LM, Shannon MF, Garson OM, Wong MA, Sutherland GR: Localization of the G-CSF gene on chromosome 17 proximal to the breakpoint in the t(15;17) in acute promyelocytic leukemia. Blood 1987 (70):330–332.PubMedGoogle Scholar
  37. 37.
    Platzer E, Oez K, Weite, K, Sandier A, Gabrilove JL, Mertelsman R, Moore MA, Kalden JR: Human pluripotent hematopoietic colony stimulating factor; activities on human and murine cells. Immunobiol 1987 (172):185–193.CrossRefGoogle Scholar
  38. 38.
    Asano S, Shirafuji N, Watari K, Matsuda S, Uemura N, Jeki R, Kodo H, Takaku F: Phase I clinical study for recombinant human granulocyte colony-stimulating factor. Behring Inst Mitt 1988 (83):222–228.PubMedGoogle Scholar
  39. 39.
    Bronchud M, Scarfte JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987 (56):809–813.PubMedCrossRefGoogle Scholar
  40. 40.
    Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Gron J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Weite K, Souza L: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy or transitional cell carcinoma of the urothelium. N Engl J Med 1988 (318):1414–1422.PubMedCrossRefGoogle Scholar
  41. 41.
    Lindemann A, Herrmann F, Oster W, Meyenburg W, Haffneer P, Souza L, Mertelsmann R: Hematologic effects of recombinat human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989 (in press).Google Scholar
  42. 42.
    Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R: Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988 (1):667–672.PubMedCrossRefGoogle Scholar
  43. 43.
    Sheridan W, Morstyn G, Green M et al: Phase II study of granulocyte colony-stimulating factor (G-CSF) in autologous bone marrow transplantation (ABMT). Proc Am Soc Clin Oncol 1990 (abstr in press).Google Scholar
  44. 44.
    Glapsy JA, Baldwin GC, Robertson PA, Souza L, Vincent M, Ambersley J, Golde DW: Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988 (109):789–795.Google Scholar
  45. 45.
    Jakubowski AA, Souza L, Kelly F, Fain K, Budman D, Clarkson B, Bonilla MA, Moore MAS, Gabrilove J: Effects of granuolcyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 1989 (320):38–42.PubMedCrossRefGoogle Scholar
  46. 46.
    Hammond WP, Price TH, Souza LM, Dale DC: Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 1989 (320):1306–1311.PubMedCrossRefGoogle Scholar
  47. 47.
    Bonilla MA, Gillio AP, Ruggiero M, Kernan NA, Brochstein JA, Abboud MA, Fumagalli L, Vincent M, Weite K, Souza LM, O’Reilly Rl: In vivo recombinant human granulocyte colony-stimulating factor (rhG-CSF) corrects neutropenia in patients with congenital agranulocytosis: Blood 1988 (72):Abstr 349.Google Scholar
  48. 48.
    Spivac JL: The mechanism of action of erythropoietin. Int J Cell Cloning 1986 (4):139–166.CrossRefGoogle Scholar
  49. 49.
    Koury ST, Bondurant MC, Koury MJ: Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988 (71):524–527.PubMedGoogle Scholar
  50. 50.
    Lacombe C, DaSilva JL, Bruneval P, Fournier JG, Wendung F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P: Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988 (81):620–623.PubMedCrossRefGoogle Scholar
  51. 51.
    Fried W: The liver as a source of extrarenal erythropoietin production. Blood 1972 (40):671–677.PubMedGoogle Scholar
  52. 52.
    Zanjani ED, Poster J, Burlington H, Mann LI, Wasserman LR: Liver as the primary site of erythropoietin formation in the fetus. J Lab Clin Med 1977 (89):640–644.PubMedGoogle Scholar
  53. 53.
    Goldberg MA, Dunning SP, Bunn HF: Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988 (242):1412–1415.PubMedCrossRefGoogle Scholar
  54. 54.
    Law ML, Cai C-H, Lin F-K, Wei A, Huang S-Z, Hartz J-H, Morse H, Lin C-H, Jones C, Kao F-T: Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc Natl Acad Sei USA 1986 (83):6920–6924.CrossRefGoogle Scholar
  55. 55.
    Ganser A, Bergmann M, Voelkers B, Gruetzmacher P, Scigalla P, Hoelzer D: In vivo effects of recombinant human erythropoietin on circulating human haematopoietic progenitor cells. Exp Hematol 1989 (17):433–435.PubMedGoogle Scholar
  56. 56.
    Geissler K, Stockenhuber F, Kabrna E, Hinterberger W, Balcke P, Lecher K: Recombinant human erythropoietin and haematopoietic progenitor cells in vivo. Blood 1989 (73):2229.PubMedGoogle Scholar
  57. 57.
    Oster W: Personal communicaton.Google Scholar
  58. 58.
    Adamson JW: The promise of recombinant human erythropoietin. Sem Hematol 1989 (26):5–8.Google Scholar
  59. 59.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anaemia of end-stage renal disease with recombinant human erythropietin. N Engl J Med 1987 (316):73–80.PubMedCrossRefGoogle Scholar
  60. 60.
    Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J: Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Int Med 1989 (110):108–114.PubMedGoogle Scholar
  61. 61.
    Oster W, Herrmann F, Cicco A, Gamm H, Zeile G, Brune T, Lindemann A, Schulz G, Mertelsmann R: Erythropoietin prevents chemotherapy-induced anemia. Blut 1989 (59):1–5.CrossRefGoogle Scholar
  62. 62.
    Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Müller G, Brune T, Kraemer H-P, Mertelsmann R: Erythropoietin (EPO) for the treatment of anemia of malignancy due to neoplastic bone marrow infiltration. J Clin Oncol (in press).Google Scholar
  63. 63.
    Yang Y-C, Ciarletta AB, Temple PA, Chung MP, Kovacic S, Witek-Giannotti JS, Leary AC, Kirz R, Donahue RE, Wong GG, Clark SC: Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 1986 (47):3–10.PubMedCrossRefGoogle Scholar
  64. 64.
    Donahue RE, Wang EA, Stone DK, Kamen R, Wong GG, Sehgal PK, Nathan DG, Clark SC: Stimulation of hematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 1986 (321):872–875.PubMedCrossRefGoogle Scholar
  65. 65.
    Weite K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, Moore MAS, O’Reilley Souza LM: Recombinant human G-CSF: Effects on hematopoiesis in normal and cyclophosphamide treated primates. J Exp Med 1987 (165):941–948.CrossRefGoogle Scholar
  66. 66.
    Ganser A, Lindemann A, Seipelt G, Oltmann OG, Herrmann F, Schulz G, Mertelsmann R, Hoelzer D: Effect of recombinant human lnterleukin-3 (rhlL-3) in patients with bone marrow failure — a phase I/II trial. Blood 1989 (74): Abstr 177.Google Scholar
  67. 67.
    Stanley ER, Hansen G, Woodcock J, Metcalf D: Colony stimulating factor and the regulation of granulopoiesis and macrophage production. Fed Proc 1975 (34):2272–2278.PubMedGoogle Scholar
  68. 68.
    Howard M, Matis L, Malek TR, Shevach E, Kehl W, Cohen D, Nakanishi K, Paul WE: Interleukin-2 induces antigen reative T cell lines to secrete BCGF-1. J Exp Med 1983 (158):2024–2039.PubMedCrossRefGoogle Scholar
  69. 69.
    Nedwin GE, Svedersky LP, Bringman TS, Palladino MA, Goeddel DV: Effect of Interleukin-2, y-interferon, and mitogens on the production of tumor necrosis factor alpha and beta. J Immunol 1985 (135):2492–2497.PubMedGoogle Scholar
  70. 70.
    Farrar WL, John HM, Farrar J: Regulation of the production of immune interferon and cytotoxic T-lymphocytes by IL-2. J Immumol 1981 (126):1120–1125.Google Scholar
  71. 71.
    Kawase I, Brooks CG, Kuribayashi K, Olabunenaga S, Newman W, Gillis S, Henney CS: Interleukin-2 induces y-interferon production: Participation of macrophages and NK-like cells. J Immunol 1983 (131):288–292.PubMedGoogle Scholar
  72. 72.
    Black CM, Catterall JR, Remington, JS: In vivo and in vitro activation of alveolar macrophages by recombinant y-lnterferon. J Immunol 1987 (138):491–495.PubMedGoogle Scholar
  73. 73.
    Murray HW, Spitalney GL, Nathan CF: Activation of mouse peritoneal macrophages in vitro and in vivo by y-lnterferon. J Immunol 1985 (134):1619–1622.PubMedGoogle Scholar
  74. 74.
    Nathan CF, Murray HW, Wiebe ME, Rubin BY: Identification of y-interferon as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983 (158):670–689.PubMedCrossRefGoogle Scholar
  75. 75.
    Schreiber RD, Celada A: Molecular characterisation of y-interferon as a macrophage activating factor. In: Pick E (ed) Lymphokines. Academic Press, New York 1985 (11) pp 87–118.Google Scholar
  76. 76.
    Malkovsky M, Loveland B, North M, Asherson GL, Gao L, Ward P, Fiers W: Recombinant interleukin-2 directly augments the toxicity of human monocytes. Nature 1987 (325):262–265.PubMedCrossRefGoogle Scholar
  77. 77.
    Phillips JH, Lanier LL: Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986 (164):814–825.PubMedCrossRefGoogle Scholar
  78. 78.
    Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985 (161):1169–1188.PubMedCrossRefGoogle Scholar
  79. 79.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shilari E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985 (313):1485–1492.PubMedCrossRefGoogle Scholar
  80. 80.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987 (316):879–889.CrossRefGoogle Scholar
  81. 81.
    West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of cancer. N Engl J Med 1987 (316):898–905.PubMedCrossRefGoogle Scholar
  82. 82.
    Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, Parkinson D: A phase II study of interleukin-2 and lymphokine activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989 (7):477–485.PubMedGoogle Scholar
  83. 83.
    Fischer Rl, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E: Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann !nt Med 1988 (108):518–523.Google Scholar
  84. 84.
    Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986 (58):2764–2772.PubMedCrossRefGoogle Scholar
  85. 85.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA: Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988 (48):5864–5867.PubMedGoogle Scholar
  86. 86.
    Fraser-Scott K, Hatzakis H, Seong D, Jones CM, Wu KK: Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase. J Clin Invest 1988 (82):1877–1883.CrossRefGoogle Scholar
  87. 87.
    Mier JW, Vachino G, Van der Meer J, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA: Induction of circulating tumor necrosis factor as the mechanism for the febrile response to interleukin-2 in cancer patients. J Clin Immunol 1988 (8):426–436.PubMedCrossRefGoogle Scholar
  88. 88.
    Lindemann A, Hoeffken K, Schmidt RE, Diehl V, Kloke O, Gamm H, Hayungs J, Oster W, Böhm M, Kolitz JE, Franks CR, Herrmann F, Mertelsmann R: A phase II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989 (28):275–281.PubMedCrossRefGoogle Scholar
  89. 89.
    Mitchell MS: Low-dose cyclophosphamide and IL-2 in the treatment of advanced melanoma. In: Berger HG et al (eds) Cancer Therapy. Springer-Verlag, Berlin, Heidelberg 1989 pp 85–89.Google Scholar
  90. 90.
    Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC: Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988 (6):409–424.PubMedGoogle Scholar
  91. 91.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzenhuber D, Wei JP, White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988 (319):1676–1680.PubMedCrossRefGoogle Scholar
  92. 92.
    Bate CAW, Taverne J, Playfair JHL: Malarial parasites induce TNF production by macrophages. Immunol 1988 (64):227–231.Google Scholar
  93. 93.
    Sayers TJ, Macker I, Chung J, Kugler E: The production of tumor necrosis factor by mouse bone marrow-derived macrophages in response to bacterial LPS and chemically synthesised monosaccharide precursors. J Immunol 1987 (138):2935–2940.PubMedGoogle Scholar
  94. 94.
    Cuturi MC, Murphy M, Costa-Giomi MP, Weinmann R, Perussia B, Trinchieri G: Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med 1987 (165):1581–1594.PubMedCrossRefGoogle Scholar
  95. 95.
    Degliantoni G, Murphy M, Kobayashi M, Francins MK, Perussia B, Trindieri G: Natural killer (NK) cell-derived hematopoietic colony inhibiting activity and NK cytotoxic factor: Relationship with tumor necrosis factor and synergisms with immune interferon. J Exp Med 1985 (162):1512–1530.PubMedCrossRefGoogle Scholar
  96. 96.
    Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Nedwin JJ, Pennica D, Goeddel DV, Gray PW: Human lymphotoxin and tumor necrosis factor genes. Stucture, homology and chromosomal location. Nucl Acids Res 1985 (13):6361–6373.PubMedCrossRefGoogle Scholar
  97. 97.
    Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynek R, Palladino MA, Kohr WJ, Aggarwl BB, Goeddel DV: Human tumor necrosis factor. Precursor, structure, expression and homology to lymphotoxin. Nature 1984 (312):724–729.PubMedCrossRefGoogle Scholar
  98. 98.
    Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA: Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factor. J Immunol 1985 (135):2069–2073.PubMedGoogle Scholar
  99. 99.
    Hori K, Ehrke MH, Mace K, Mihich E: Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and y-interferon. Cancer Res 1987 (47):5868–5874.PubMedGoogle Scholar
  100. 100.
    Ostensen ME, Thiele DL, Lipsky PE: Tumor necrosis factor alpha enhances cytolytic activity of human natural killer cells. J Immunol 1987 (138):4185–4191.PubMedGoogle Scholar
  101. 101.
    Old LJ: Tumor necrosis factor (TNF). Science 1985 (230):630–632.PubMedCrossRefGoogle Scholar
  102. 102.
    Collins T, Lapierre LA, Fiers W, Strominger JL, Prober JS: Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Nat Acad Sci (Wash) 1986 (83):446–450.CrossRefGoogle Scholar
  103. 103.
    Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM: An endothelial ceil surface factor(s) induced in vitro by lipopolysaccharide, interleukin-1 and tumor necrosis factor-alpha increases neutophil adherence by a CDw 18-independent mechanism. J Immunol 1986 (135):4533–4548.Google Scholar
  104. 104.
    Van De Wiel PA, Pieters RHH, Bloksma N: Synergistic action of recombinant TNF and endotoxin on cultured endothelial cells. Immunobiol 1987 (175):75.Google Scholar
  105. 105.
    Leibovich SJ, Polverini PJ, Shephard MJ, Wiseman MJ, Shively DM, Nuseir V: Macrophage-induced angiogenesis is mediated by tumor necrosis factor alpha. Nature 1987 (329):630–632.PubMedCrossRefGoogle Scholar
  106. 106.
    Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM: Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells. Science 1985 (230):943–945.PubMedCrossRefGoogle Scholar
  107. 107.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore D, Williamson B: An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci (USA) 1975 (72):3666–3670.CrossRefGoogle Scholar
  108. 108.
    Haranaki K, Carswell EA, Williamson B, Pentergast JS, Satomi N, Old LJ: Purification, characterisation and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc Natl Acad Sci USA 1986 (83):3949–3953.CrossRefGoogle Scholar
  109. 109.
    Blick M, Sherwin SA, Rosenblum M, Gutterman J: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987 (47):2986–2989.PubMedGoogle Scholar
  110. 110.
    Mertelsmann R, Gamm H, Flener Fl, Herrmann F: Recombinant human tumor necrosis factor alpha (rhTNF-alpha) in advanced cancer: A phase I clinical trial. Proceedings of AACR 1987 (28): Abstr. 1583.Google Scholar
  111. 111.
    Bevilacqua MP, Pober JS, Mendrick DL, Cotram RS, Gimbrone MA: Identification of an inducible endothelial leukocyte adhesion molecule, E-LAM 1. Proc Nat Acad Sci (Wash) 1988 (in press).Google Scholar
  112. 112.
    Pober JS, Gimbrone MA, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA: Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor and imune interferon. J Immunol 1986 (137):1893–1896.PubMedGoogle Scholar
  113. 113.
    Haranaka K, Satomi N, Sakurai A, Haranaka R: Necrotizing activity of tumor necrosis factor and its mechanism. Ann Inst Pasteur/Immunol 1988 (139):288–294.CrossRefGoogle Scholar
  114. 114.
    Strander H: Anti-tumor effects of interferon and its possible use as an anti-neoplastic agent in man. Texas Rep Biol Med 1977 (35):429.Google Scholar
  115. 115.
    Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung HF, Pestka S: Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 1982 (67):160–167.PubMedCrossRefGoogle Scholar
  116. 116.
    Lindahl P, Gresser I, Leary P et al: Enhanced expression of histocompatibility antigens of lymphoid cells treated with interferon. J Infect Dis 1976 (133 Suppl):A66.PubMedCrossRefGoogle Scholar
  117. 117.
    Brodeur BR, Merigan TC: Mechamism of the suppressive effect of interferon on antibody synthesis in vivo. J Immunol 1975 (114):1323–1328.PubMedGoogle Scholar
  118. 118.
    Schnaper HW, Aune TM, Pierce CW: Suppressor T cell activation by human leukocyte interferon. J Immunol 1983 (131):2301–2306.PubMedGoogle Scholar
  119. 119.
    Vilcek J, Gray PW, Rinderknecht E, Sevastopoulos CG: Interferon-y: A lymphokine for all seasons. In: Pick E (ed) Lymphokines. Academic Press, New York 1985 (11) pp 1–32.Google Scholar
  120. 120.
    Quesada JR, Keuben J, Manning JJ, Hersh EM, Gutterman JU: Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984 (310):15–18.PubMedCrossRefGoogle Scholar
  121. 121.
    Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986 (314):1065–1069.PubMedCrossRefGoogle Scholar
  122. 122.
    Groopman JE, Gottlieb MS, Godman J, Hisugasu RT, Conant MA, Prince H, Faney JU, Derezin M, Weinstein WM, Casavante C, Rothman J, Rudnik SA, Volberding PA: Recombinant alpha-2-interferon therapy for Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. Ann Intern Med 1984 (100):671–676.PubMedGoogle Scholar
  123. 123.
    Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, O’Fallon JR, Itri LM: Phase II study of recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 1984b (2):1002–1005.PubMedGoogle Scholar
  124. 124.
    Niederle N, Kummer G: The role of interferon in the management of patients with hairy cell leukemia and multiple myeloma. In: Berger HG et al (eds):Cancer Therapy. Springer-Verlag, Berlin, Heidelberg 1989 pp 112–123.Google Scholar
  125. 125.
    Aulitzky W, Gastl G, Tilg H. v. Lhttichau I, Flener R, Huber C: Recurrence of hairy cell leukemia upon discontinuation of IFN treatment. Blut 1986 (53):215.Google Scholar
  126. 126.
    Porzsolt F, Digel W, Buck C, Raghavachar A, Stefanie M, Schöniger W: Possible mechanism of interferon action in hairy cell leukemia. In: Berger HG et al (eds) Cancer Therapy. Springer-Verlag, Berlin, Heidelberg 1989 pp 126–131.Google Scholar
  127. 127.
    Lindemann A, Ludwig WD, Oster W, Mertelsmann R, Herrmann F: High level secretion of TNF-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood 1989 (73):880–884.PubMedGoogle Scholar
  128. 128.
    Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Sustained complete cytogenetic response among Philadelphia positive chronic myelogenous leukemia (CML PH1) patients treated with alpha interferon. Blood 1989 (74): Abstr 289.Google Scholar
  129. 129.
    Higano CS, Raskind W, Durnam D, Singer JW: Alpha interferon (IF) induces cytogenetic remissions in patients who relapse with chronic myelogenous leukemia (CML) after allogenic bone marrow transplantation (BMT). Blood 1989 (74): Abstr 307.Google Scholar
  130. 130.
    Kantarjian H, Keating M, McCredie K, Gutterman J, Freireich E, Deisseroth A, Talpaz M: Treatment of advanced stages of Philadelphia-chromosome (Ph)-positive chronic myelogenous leukemia (CL) with alpha interferon (IFN-alpha) and low-dose cytosine arabinoside (Ara-C). Blood 1989 (4): Abstr 878.Google Scholar
  131. 131.
    Jones GJ, Itri LM: Safety and tolerance of recombbinant interferon alpha-2a (Roferon-A) in cancer patients. Cancer 1986 (57):1709–1715.PubMedCrossRefGoogle Scholar
  132. 132.
    Bunn PA, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, Weach SR, Zeffren J, Sherwins S, Oldham R: Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Int Med 1984 (101):484–487.PubMedGoogle Scholar
  133. 133.
    Foon KA, Sherwin SA, Abrams PG, Kongo DU, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J, Jaffe ES, Oldhorn RK: Treatment of advanced Non-Hodgkinfs lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984 (311):1148–1152.PubMedCrossRefGoogle Scholar
  134. 134.
    Einzig Al, Krown SE, Oettgen HF: Recombinant leukocyte A interferon (rlFNa-A) in renal cell cancer (RCC). Proc Am Soc Clin Oncol 1984 (3): Abstr C209.Google Scholar

Copyright information

© Spinger-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • F. M. Rosenthal
    • 1
  • A. Lindemann
    • 1
  • F. Herrmann
    • 1
  • R. Mertelsmann
    • 1
  1. 1.Department of Medicine I, Division of Haematology/OncologyAlbert-Ludwig’s University Medical CentreFreiburgGermany

Personalised recommendations